Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALLO 316

Next Previous
Drug Profile

ALLO 316

Alternative Names: ALLO-316; AlloCAR T™; AlloCAR T™ Therapy - Allogene Therapeutics; Anti-CD70 CAR T cell therapy - Allogene Therapeutics; CD70 targeted CAR-T cell therapy - Allogene Therapeutics

Latest Information Update: 17 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellectis
  • Developer Allogene Overland Biopharm; Allogene Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Renal cell carcinoma
  • Preclinical Acute myeloid leukaemia; Haematological malignancies; Solid tumours
  • No development reported Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Jun 2025 Updated efficacy and adverse events data from the phase I TRAVERSE trial in Renal cell carcinoma released by Allogene Therapeutics
  • 07 Nov 2024 Adverse events and efficacy data from the phase-I TRAVERSE trial in Renal cell carcinoma released by Allogene Therapeutics ,
  • 29 Oct 2024 ALLO 316 receives Regenerative Medicine Advanced Therapy (RMAT) status for Renal cell carcinoma (Late-stage disease, Metastatic disease) in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top